ID | 114836 |
著者 | |
キーワード | Hypertension
Diabetes Mellitus
Renin-Angiotensin System (RAS) Inhibitors
Angiotensin-Converting Enzyme (ACE) Inhibitors
Angiotensin Receptor Blockers (ARB)
|
資料タイプ |
学術雑誌論文
|
抄録 | Currently, major categories of antihypertensive agents include diuretics, beta-blockers, calcium channel blockers (CCBs), renin-angiotensin system (RAS) inhibitors [angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB)]. Among them, RAS (ACE inhibitors and ARB) would be recommended to be a first-line treatment when providing antihypertensive agents for hypertensive patients with diabetes, cardiovascular disease, and impaired renal function. Randomized controlled trials (RCT) of RAS inhibitors compared with other antihypertensive showed a rather lower relative risk (RR). They are all-cause death (RR - 0.95), cardiovascular death (RR - 0.84), incidence of cardiovascular disease (RR - 0.93), and incidence of renal dysfunction (RR - 0.91).
|
掲載誌名 |
Diabetes Research : Open Access
|
出版者 | Asploro
|
巻 | 2
|
号 | 1
|
開始ページ | 4
|
終了ページ | 8
|
発行日 | 2020-04-16
|
権利情報 | © 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
|